Mylan's (MYL) EpiPen Settlement is Credit-Negative Development - Moody's
Get Alerts MYL Hot Sheet
Join SI Premium – FREE
Moody's Investors Service commented that Mylan's (Nasdaq: MYL) settlement with the US Department of Justice and other government agencies to resolve EpiPen's reimbursement classification with the Centers for Medicaid and Medicare Services is a credit negative development. There are no changes to Mylan N.V.'s Baa3 rating or the stable ratings outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Global (PARA) Cut to Junk By the S&P
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors ServiceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!